title: Endogenous anti-inflammatory mediators from arachidonate in human neutrophils.
abstract: Eicosanoids have been historically involved in the pathogenesis of various inflammatory diseases. Lipoxins (LXs) and epi-LXs show physiological effects relevant to inflammation regulation. In this study, we focused on LX precursors based on the hypothesis that their entrance and metabolism into the cell may facilitate their targeting at the inflammation site. Because compound chirality is of considerable importance in the efficacy of therapeutic agents, our aim was to study the anti-inflammatory effects of various epimers of LXA(4) precursors compared to LXA(4). Blood polymorphonuclear cells (PMNs) were incubated with 15(S)- or 15(R)-hydroxyeicosatetraenoic acid (HETE), 14(R)-,15(S)-, or 14(S),15(S)-diHETE, and LXA(4) and then stimulated with the calcium ionophore A23187. We found that 15(R)-HETE rather than 15(S)-HETE was preferentially metabolized and that 15-epi-LXs were produced in larger amounts than LXs. In contrast, when PMNs were incubated with the diastereoisomers of 14,15(S)-diHETE, 14-epi-LXB(4) was produced in lower amounts than LXB(4). Enantiomers of 15-HETE and diastereoisomers of 14,15-diHETE and LXA(4) were able to significantly decrease LTB(4) release by PMNs. These results suggest a potential resolution of the inflammatory process through endogenous anti-inflammatory mediators released by the way of trans-cellular metabolism.
authors.affiliation: Inserm U 454, IFR-3, CHU de Montpellier, Hôpital Arnaud de Villenueve, 371 Av du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France.
authors.forename: I
authors.initials: I
authors.lastname: Vachier
authors.forename: P
authors.initials: P
authors.lastname: Chanez
authors.forename: C
authors.initials: C
authors.lastname: Bonnans
authors.forename: P
authors.initials: P
authors.lastname: Godard
authors.forename: J
authors.initials: J
authors.lastname: Bousquet
authors.forename: C
authors.initials: C
authors.lastname: Chavis
mesh_terms: D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D016718:Arachidonic Acid / Q000737:chemistry / Q000494:pharmacology*; D002851:Chromatography, High Pressure Liquid; D004305:Dose-Response Relationship, Drug; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids / Q000737:chemistry / Q000494:pharmacology; D044045:Lipoxins; D009504:Neutrophils / Q000187:drug effects* / Q000276:immunology* / Q000378:metabolism; D013237:Stereoisomerism
chemical_list: D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D006893:Hydroxyeicosatetraenoic Acids; D044045:Lipoxins; C040527:lipoxin A4; D016718:Arachidonic Acid; C025984:15-hydroxy-5,8,11,13-eicosatetraenoic acid